Anika Therapeutics, Inc. — Q1 2017 Form 10-Q Summary
Business context and reporting period
Anika Therapeutics is an integrated orthopedic medicines company focused on hyaluronic-acid-based products, including ORTHOVISC, MONOVISC, CINGAL, and HYALOFAST. The filing reports unaudited results for the three months ended March 31, 2017, compared with the same period in 2016.
Key financial metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Total revenue | $23.4 million | $22.3 million | +5% |
| Product revenue | $23.4 million | $22.3 million | +5% |
| Product gross profit | $17.3 million | $16.9 million | +3% |
| Product gross margin | 74% | 76% | Down 2 points |
| Operating income | $8.0 million | $10.7 million | -25% |
| Net income | $5.5 million | $6.9 million | -20% |
| Diluted EPS | $0.37 | $0.45 | Down $0.08 |
| Operating cash flow | $15.5 million | $8.0 million | +$7.4 million |
Operating margin was approximately 34% versus 48% in the prior-year quarter, while net margin was approximately 23% versus 31%. The decline primarily reflected higher research and development and selling, general and administrative expenses.
At March 31, 2017, cash and cash equivalents were $119.4 million, investments were $19.3 million, and total current assets were $177.1 million. Working capital was approximately $166.8 million. The filing does not report material borrowings or debt; current liabilities were $10.2 million and other long-term liabilities were $0.4 million, excluding deferred tax liabilities.
Material changes versus the prior comparable period
- Orthobiologics revenue increased 3% to $20.2 million, led by a 24% increase in worldwide MONOVISC revenue and contributions from CINGAL and ORTHOVISC-T.
- Other product revenue increased 44% to $1.4 million, primarily due to higher HYVISC veterinary-product demand.
- Dermal revenue increased 12% to $0.4 million, while surgical revenue decreased 2% to $1.3 million.
- Research and development expense increased 96% to $4.2 million, primarily due to HYALOFAST and CINGAL clinical and regulatory activities and other development programs.
- SG&A expense increased 27% to $5.1 million due to personnel costs, professional fees, marketing initiatives, and support for international launches.
- Gross margin declined because of inventory write-offs related to a product component change.
- Cash flow benefited from the timing of accounts payable and income-tax payments. The prior-year period included a $25.0 million accelerated share repurchase; no comparable repurchase occurred in Q1 2017.
- Effective tax rate decreased to 31.9% from 36.1%, including a $0.3 million discrete tax benefit from share-based compensation.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects orthobiologics revenue to continue growing during 2017, supported by MONOVISC, international CINGAL availability, and broader viscosupplementation demand.
- Management expects modest surgical growth, increased dermal and other revenue, higher R&D spending, and higher SG&A expense during 2017.
- The Bedford manufacturing project is expected to cost approximately $25 million in total; approximately $22.5 million had been spent through March 31, 2017, with completion expected before year-end 2017.
- A second U.S. Phase III CINGAL trial began during the first quarter, with the first patient expected to be treated in the second quarter of 2017. CINGAL remained subject to FDA/CDER approval requirements and an eventual NDA process.
- The company expects to continue investing in HYALOFAST, CINGAL, and other regenerative-medicine programs. The filing provides no numerical full-year earnings or revenue guidance.
- Anika’s new Italian facility lease began March 1, 2017, with an initial annual rent of approximately $0.3 million and an initial 15-year term.
- Normal-course legal proceedings, product warranties, regulatory approvals, intellectual-property protection, product commercialization, competition, key personnel, and clinical-development execution remain principal risks. Management does not expect current legal proceedings to have a material adverse effect.
- Management stated that available cash, investments, and operating cash flow are adequate to support the business for at least the next twelve months, although additional financing could be required if future resources are insufficient.
Most important facts for investors to verify
- Whether MONOVISC, CINGAL, and ORTHOVISC-T growth offsets the ongoing shift away from multi-injection ORTHOVISC and supports the company’s 2017 revenue outlook.
- The timing, cost, and commercial impact of the Bedford manufacturing transition and facility completion.
- Progress, enrollment, cost, and FDA requirements for the additional CINGAL Phase III trial and NDA pathway.
- Whether elevated R&D and SG&A spending produces corresponding product launches and revenue growth.
- The sustainability of the 74% product gross margin after the reported inventory write-offs.
- Potential effects of foreign exchange, regulatory decisions, clinical outcomes, patent matters, and distributor concentration on future results.
- The impact of ASU 2016-09 adoption and other pending accounting standards on future reported earnings, taxes, and disclosures.